Possible modification of BRSK1 on the risk of alkylating chemotherapy-related reduced ovarian function

STUDY QUESTION: Do genetic variations in the DNA damage response pathway modify the adverse effect of alkylating agents on ovarian function in female childhood cancer survivors (CCS)? SUMMARY ANSWER: Female CCS carrying a common BR serine/threonine kinase 1 (BRSK1) gene variant appear to be at 2.5-f...

Descripción completa

Detalles Bibliográficos
Autores principales: van der Kooi, Anne-Lotte L F, van Dijk, Marloes, Broer, Linda, van den Berg, Marleen H, Laven, Joop S E, van Leeuwen, Flora E, Lambalk, Cornelis B, Overbeek, Annelies, Loonen, Jacqueline J, van der Pal, Helena J, Tissing, Wim J, Versluys, Birgitta, Bresters, Dorine, Beerendonk, Catharina C M, Ronckers, Cécile R, van der Heiden-van der Loo, Margriet, Kaspers, Gertjan L, de Vries, Andrica C H, Robison, Leslie L, Hudson, Melissa M, Chemaitilly, Wassim, Byrne, Julianne, Berger, Claire, Clemens, Eva, Dirksen, Uta, Falck Winther, Jeanette, Fosså, Sophie D, Grabow, Desiree, Haupt, Riccardo, Kaiser, Melanie, Kepak, Tomas, Kruseova, Jarmila, Modan-Moses, Dalit, Pluijm, Saskia M F, Spix, Claudia, Zolk, Oliver, Kaatsch, Peter, Krijthe, Jesse H, Kremer, Leontien C, Yasui, Yutaka, Brooke, Russell J, Uitterlinden, André G, van den Heuvel-Eibrink, Marry M, van Dulmen-den Broeder, Eline
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2021
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7970730/
https://www.ncbi.nlm.nih.gov/pubmed/33582778
http://dx.doi.org/10.1093/humrep/deaa342

Ejemplares similares

Ejemplares similares